Related Experiment Video
Updated: Jun 5, 2026
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
Evidence for acute neurotoxicity after chemotherapy
Axel Petzold1, Tjeerd Mondria, Jens Kuhle
1Department of Neuroimmunology, UCL Institute of Neurology, Queen Square, London, United Kingdom. a.petzold@vumc.nl
Annals of Neurology
|January 4, 2011
Summary
Chemotherapy causes acute neurotoxicity, evidenced by increased neurofilament levels and brain atrophy in patients undergoing bone marrow transplants. This neurotoxicity correlates with disability progression, highlighting it as an adverse side effect.
Area of Science:
- Neuroscience
- Oncology
- Immunology
Background:
- Chronic neurotoxicity is a known complication of chemotherapy, impacting patient quality of life.
- Acute neurotoxicity following chemotherapy requires further investigation, particularly in vulnerable patient populations.
Purpose of the Study:
- To investigate the occurrence and characteristics of acute neurotoxicity in patients undergoing chemotherapy for bone marrow transplantation.
- To assess neurodegeneration using clinical, biochemical, and imaging markers.
Main Methods:
- Prospective study of patients with secondary progressive multiple sclerosis (SPMS-BMT) and hematological malignancies (HM-BMT) receiving chemotherapy.
- Control groups included SPMS patients (SPMS-PL) and healthy individuals.
- Neurodegeneration assessed via Expanded Disability Status Scale (EDSS), serum neurofilaments (NfH-SMI35), and MRI-based brain atrophy.
Main Results:
- Chemotherapy significantly increased disability progression compared to placebo.
- Serum NfH-SMI35 levels rose sharply post-chemotherapy in SPMS-BMT and HM-BMT groups, unlike controls.
- Elevated NfH-SMI35 levels correlated with sustained disability progression and increased brain atrophy rates.
Conclusions:
- Neurotoxicity is an acute, undesirable side effect of aggressive chemotherapy regimens.
- Early detection of neurotoxicity using biomarkers like NfH-SMI35 is crucial.
- Findings underscore the need for neuroprotective strategies during chemotherapy.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:26Toxic Reactions: Overview
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...